|
Session 145
Poster Abstracts
Cardiovascular, Lipid, and Metabolic Complications of ART
Tuesday, 1 - 4 pm
Poster Hall |
807
 |
Surveillance Data for Myocardial Infarction Hospitalizations among HIV+ and HIV- Northern Californians: 1994 - 2006
Daniel Klein*1, L Hurley2, M Silverberg2, M Horberg2, C Quesenberry2, and S Sidney2
1Kaiser Permanente, Hayward, CA, US and 2Kaiser Permanente, Oakland, CA, US |
| 808 |
Predicting the Risk of Coronary Heart Disease in HIV-infected Patients: The D:A:D Risk Equation
Nina Friis-Møller*1, R Thiébaut2, P Reiss3, W El-Sadr4, S Worm1, O Kirk1, A Phillips5, C Sabin5, J Lundgren1, M Law6, and The D:A:D Study Group
1Copenhagen HIV Prgm, Hvidovre Univ Hosp, Denmark; 2INSERM E0338 & U593, ISPED, Univ Victor Segalen Bordeaux 2, France; 3ATHENA, HIV Monitoring Fndn, Academic Med Ctr, Amsterdam, The Netherlands; 4CPCPRA, Columbia Univ and Harlem Hosp, New York, NY, US; 5Royal Free Ctr for HIV Med, Royal Free and Univ Coll London, UK; and 6Australian HIV Observational Database, Natl Ctr in HIV Epidemiology and Clin Res, Sydney |
| 809 |
Predicted Risk of Coronary Heart Disease with Tipranavir Exposure Compared to Conventional PI in the RESIST Trial
Nina Friis-Møller*1, M Kraft2, H Valdez3, D Hall3, and J Lundgren1
1Copenhagen HIV Prgm, Hvidovre Univ Hosp, Denmark; 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany; and 3Boehringer Ingelheim Pharma, Ridgefield, CT, US |
| 810 |
Carotid Intima-media Thickness, Coronary Artery Calcium Scores, and Framingham Risk Scores among HIV-infected Patients in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy
Kristin Mondy*1, K Henry2, E Overton1, T Bush3, L Conley3, K Lichtenstein4, E Kojic5, W Mack6, H Hodis6, J Brooks3, and SUN Study Investigators
1Washington Univ Sch of Med, St Louis, MO, US; 2HIV Prgm, Hennepin County Med Ctr, Univ of Minnesota, Minneapolis, US; 3CDC, Atlanta, GA, US; 4Univ of Colorado Hlth Sci Ctr, Denver, US; 5The Miriam Hosp, Providence, RI, US; and 6Univ of Southern California, Los Angeles, US |
811
|
Clinical and Angiographic Features of Acute Coronary Syndromes in HIV-infected Compared with Non-HIV-infected Patients
F Boccara1, M Mary-Krause2, E Teiger1, S Lang1, P Lim1, K Wahbi1, J Collet1, F Beygui1, Dominique Costagliola*2, A Cohen1, and Sponsored by the French National Agency for Research on AIDS and Viral Hepatitis
1Univ Paris V, VI, XII, Paris, France and 2INSERM UMR S720, Paris, France |
812
|
Current Alcohol Consumption and Cardiovascular Disease among Men Infected with HIV
Matthew Freiberg*1, K Kraemer1, J Samet2, J Conigliaro3, R Ellison2, K Bryant4, L Kuller1, A Justice5, and Veterans Aging Cohort Study Project Team
1Univ of Pittsburgh, PA, US; 2Boston Univ, MA, US; 3Univ of Kentucky, Lexington, US; 4Natl Inst on Alcohol Abuse and Alcoholism, NIH, Rockville, MD, US; and 5West Haven VAMC and Yale Univ, New Haven, CT, US |
813
|
Increased Fat and Cholesterol Intake and Relationship to Serum Lipid Levels among HIV-infected Patients in the Current Era of HAART
H Keogh1, T Joy1, C Hadigan1,2, C Hadigan1,2, K Fitch1, S You1, J Liebau1, J Lo1, S Johnsen1, S Dolan1, and Steven Grinspoon*1
1Massachusetts Gen Hosp, Boston, US and 2NIH, Bethesda, MD, US |
| 814 |
Lipid-lowering Therapy Responses in HIV+ and HIV- Dyslipidemic Patients Enrolled in a Large Integrated Healthcare Delivery System
Michael Silverberg*, W Leyden, M Horberg, L Hurley, A Go, C Quesenberry, and D Klein
Kaiser Permanente, Oakland, CA, US |
| 815 |
Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease than the Sum of its Components: Data from the D:A:D Study
Signe W Worm*1, C Sabin2, P Reiss3, W El-Sadr4, A D'Arminio Monforte5, M Law6, M Rickenback7, S De Wit8, J Lundgren1, N Friis-Moller1, and The D:A:D Study Group
1Copenhagen HIV Prgm, Hvidovre, Denmark; 2Royal Free Ctr for HIV Med, Royal Free and Univ Coll London, UK; 3ATHENA, HIV Monitoring Fndn, Academic Med Ctr, Amsterdam, The Netherlands; 4CPCPRA, Columbia Univ and Harlem Hosp, New York, NY, US; 5ICONA, Hosp San Paolo, Univ of Milan, Italy; 6Australian HIV Observational Database, Natl Ctr in HIV Epidemiology and Clin Res, Sydney; 7Swiss HIV Corhort Study, Univ Hosp Lausanne; and 8Ctr Hosp Univ St Pierre, Brussels, Belgium |
816
|
Underutilization of Recommended Interventions for Prevention of Cardiovascular Disease in HIV-infected Patients with Established Cardiovascular Disease or Diabetes
Caroline Sabin*1, R Weber2, E Fontas3, F Dabis4, P Reiss5, S De Wit6, O Kirk7, S Worm8, N Friis-Møller8, J Lundgren8, and The D:A:D Study Group
1Royal Free Ctr for HIV Med, Royal Free and Univ Coll London, UK; 2Swiss HIV Corhort Study, Univ Hosp Zuric; 3Nice Cohort, Ctr Hosp Univ Nice, Hosp de l'Archet, France; 4INSERM E0338 & U593, ISPED, Univ Victor Segalen Bordeaux 2, France; 5ATHENA, HIV Monitoring Fndn, Academic Med Ctr, Amsterdam, The Netherlands; 6Ctr Hosp Univ St Pierre, Brussels, Belgium; 7EuroSIDA, Copenhagen HIV Prgm, Hvidovre Univ Hosp, Denmark; and 8Copenhagen HIV Prgm, Hvidovre, Denmark |
817
|
Factors Associated with the Incidence of Diabetes Mellitus in HIV-infected Participants of the Swiss HIV Cohort Study
Bruno Ledergerber*1, H Furrer2, M Rickenbach3, M Battegay4, B Hirschel5, M Cavassini5, E Bernasconi6, P Vernazza7, and R Weber1
1Univ Hosp, Zurich, Switzerland; 2Univ Hosp, Berne, Switzerland; 3Swiss HIV Corhort Study Data Ctr, Lausanne; 4Univ Hosp, Basel, Switzerland; 5Univ Hosp Geneva, Switzerland; 6Hosp Civico, Lugano, Switzerland; and 7Cantonal Hosp, St Gall, Switzerland |
| 818 |
Effects of Atazanavir or Saquinavir Once Daily with Ritonavir 100 mg and Tenofovir/Emtricitabine as Initial Therapy for HIV-1 Infection on Peripheral Glucose Disposal: A Randomized Open-label Study
Akil Jackson*, N Patel, G Lo, B Gazzard, and G Moyle
Chelsea and Westminster Hosp, London, UK |
| 819 |
Evaluation of Intracranial Hemorrhage in 49,610 HIV-infected Veterans and California Medicaid Recipients
Shawn L Fultz*1,2, Shawn L Fultz*1,2, D Zingmond3, K Gordon2, J Goulet2, L Mole4, J King, Jr1,2, J King, Jr1,2, D Bravata1,2, D Bravata1,2, H Valdez5, M Kraft6, A Justice1,2, A Justice1,2, and VACS Project Team
1VA Connecticut Hlthcare System, West Haven, US; 2Yale Univ Sch of Med, New Haven, CT, US; 3Univ of California, Los Angeles, US; 4VA Palo Alto Hlthcare System, CA, US; 5Boehringer Ingelheim Pharma, Ridgefield, CT, US; and 6Boehringer Ingelheim Pharma, Inc, Ingelheim, Germany |
| 820 |
Venous Thromboembolism in Patients with HIV: A Case-control Study
Aima Ahonkhai*, K Gebo, M Streiff, R Moore, and J Segal
Johns Hopkins Univ Sch of Med, Baltimore, MD, US |
|
